Treatment-Free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries

Treatment-Free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries

We’re pleased to share that the New England Journal of Medicine has published our “Letter to the Editor” on treatment-free remission for chronic myeloid leukemia in low- and middle-income countries!

It was written in collaboration with Dr. Jerry Radich from the Fred Hutchinson Cancer Research Center and partner physicians from Armenia, the Dominican Republic, El Salvador, Ethiopia, Honduras, India, Kenya, and Paraguay.

Read More

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • CMLPath to Care

    CMLPath to Care

    In 2017 The Max Foundation, through its subsidiary MaxAid, and Novartis have renewed their commitment to patients by launching CMLPath to Care™ a new collaboration aimed at providing humanitarian access to treatment for CML and other rare cancers for those patients for whom no other form of local treatment access exists today. CMLPath to Care consists of humanitarian product donations and funding support from Novartis to Max, and an innovative new distribution model developed and implemented by Max and its international distributor, under the Max Access Solution umbrella.

  • The Max Foundation welcomes John Menapace as CFO/VP of Administration

    The Max Foundation welcomes John Menapace as CFO/VP of Administration

    We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration. John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies.  His prior roles include positions….

  • The Max Foundation and Cepheid expand collaboration to increase access to diagnostics

    The Max Foundation and Cepheid expand collaboration to increase access to diagnostics

    The Max Foundation and Cepheid have renewed and expanded their collaboration to increase access to molecular diagnostics in low- and middle-income countries (LMICs).